Ghost Tree Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Ghost Tree Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-500,000	Closed	-$6.86M	–	102
2016 Q2	$6.86M	Buy	+500,000	New	+$7.31M	1.98%	19

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

Ghost Tree Capital's CLVS Position: Q2 2018 in Review

Ghost Tree Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 75,000 shares — an estimated $3.96M sold.

Ghost Tree Capital first reported a position in CLVS in Q4 2013 and held it in 9 quarters. The position peaked at $18M in Q3 2016. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

Ghost Tree Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
Ghost Tree Capital sold 75,000 Clovis Oncology, Inc. shares in Q2 2018, an estimated $3.96M.
Ghost Tree Capital first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 9 quarters.
Ghost Tree Capital's Clovis Oncology, Inc. position peaked at $18M in Q3 2016.
210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.